Mycobacterium tuberculosis-derived circulating cell-free DNA in patients with pulmonary tuberculosis and persons with latent tuberculosis infection.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
03
2021
accepted:
14
06
2021
entrez:
24
6
2021
pubmed:
25
6
2021
medline:
18
11
2021
Statut:
epublish
Résumé
The timely diagnosis of pulmonary tuberculosis (PTB) is challenging. Although pathogen-derived circulating cell-free DNA (cfDNA) has been detected in humans, the significance of Mycobacterium tuberculosis (MTB)-cfDNA detection in patients with PTB remains unclear. This study enrolled patients with PTB and persons with latent tuberculosis infection (LTBI) as the study and control groups, respectively, from 2018 to 2020. We measured interferon-γ levels and calculated blood monocyte-to-lymphocyte ratio (MLR). We conducted plasma cfDNA extraction, quantitative polymerase chain reaction (qPCR), and droplet digital PCR targeting the IS6110 gene of MTB. We calculated the sensitivity and specificity of using MTB-cfDNA to identify PTB and analyzed the factors associated with PTB diagnosis and MTB-cfDNA positivity. We enrolled 24 patients with PTB and 57 LTBI controls. The sensitivity of using MTB-cfDNA to identify PTB was 54.2%(13/24) in total and 46.2%(6/13) in smear-negative cases. Two LTBI controls (3.5%) tested positive for MTB-cfDNA, indicating a specificity of 96.5%(55/57). By using MTB-cfDNA positivity and an MLR ≥0.42 to identify PTB, sensitivity increased to 79.2%(19/24). Among patients with PTB, MTB-specific interferon-γ levels were higher in MTB-cfDNA positive participants than in those who tested negative (7.0 ±2.7 vs 2.7±3.0 IU/mL, p<0.001). MTB-cfDNA levels declined after 2 months of anti-tuberculosis therapy (p<0.001). The sensitivity of using MTB-cfDNA to identify PTB in participants was 54.2%, which increased to 79.2% after incorporating an MLR ≥0.42 into the analysis. MTB-cfDNA positivity was associated with MTB-specific immune response, and MTB-cfDNA levels declined after treatment. The clinical value of MTB-cfDNA in PTB management necessitates further investigation.
Identifiants
pubmed: 34166477
doi: 10.1371/journal.pone.0253879
pii: PONE-D-21-07152
pmc: PMC8224927
doi:
Substances chimiques
Cell-Free Nucleic Acids
0
DNA, Bacterial
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0253879Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Front Cell Infect Microbiol. 2017 Aug 11;7:369
pubmed: 28848722
BMC Res Notes. 2018 Oct 23;11(1):757
pubmed: 30352614
J Clin Microbiol. 2018 Sep 25;56(10):
pubmed: 30068533
Clin Chem. 2013 Jun;59(6):892-902
pubmed: 23570709
Tuberculosis (Edinb). 2016 Jul;99:47-53
pubmed: 27450004
Emerg Microbes Infect. 2018 Apr 24;7(1):78
pubmed: 29691363
BMC Infect Dis. 2020 Sep 7;20(1):657
pubmed: 32894079
AAS Open Res. 2020 Jul 29;3:34
pubmed: 32832853
Sci Rep. 2018 Jan 12;8(1):645
pubmed: 29330384
Int J Infect Dis. 2019 Feb;79:1-3
pubmed: 30399446
PLoS One. 2017 Feb 16;12(2):e0171358
pubmed: 28208160
Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419827174
pubmed: 30791749
J Thorac Dis. 2013 Jun;5(3):251-7
pubmed: 23825755
J Microbiol Immunol Infect. 2016 Aug;49(4):575-83
pubmed: 26694909
Lancet. 2015 Dec 5;386(10010):2334-43
pubmed: 26515675
J Clin Microbiol. 2019 Mar 28;57(4):
pubmed: 30404942
J Immunol Res. 2015;2015:793292
pubmed: 26339660
MMWR Recomm Rep. 2010 Jun 25;59(RR-5):1-25
pubmed: 20577159
Tuberc Respir Dis (Seoul). 2015 Apr;78(2):64-71
pubmed: 25861338
BMC Infect Dis. 2019 May 2;19(1):371
pubmed: 31046692
Clin Microbiol Rev. 2018 Jul 18;31(4):
pubmed: 30021818